Drugs / BMC128
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05354102 | May 2022 → May 2024 | melanoma, non-small cell lung carcinoma, renal cell carcinoma | Biomica Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMC128 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05354102 ↗ |
| Modality | Other / unclassified | “A live bio-therapeutic product composed of 4 commensal bacterial strains, natural inhabitants of the human intestinal tract.” NCT05354102 ↗ |
| Route | Oral | “One BMC128 capsule will be administered once daily QD” NCT05354102 ↗ |